tbuckley/cabot-search huggingface dataset:
Abstract P154: Blood Pressure and Lipid Control Variation in Faculty versus Trainee Clinics
Authors: Sarina Sachdev, Bassam A Omar, Christopher Malozzi, G. Mustafa Awan
Journal: Circulation (2018)

Background: Clinics run by trainees are often composed of indigent patients with challenging problems as to implementation of preventive measures. Methods: Charts were selected based on the inclusion of hypertension as a diagnosis; 100 visits were reviewed in each of two groups. The first group (clinic 1) included patients seen by a cardiologist faculty; all patients had insurance. The second group (clinic 2) included visits seen by cardiology fellows, and directly supervised by the same faculty physician; with the majority of these patients lacking insurance. The difference between the groups with regards to age, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and LDL cholesterol were analyzed using Student's t-Test. Results: The mean age of patients in clinic 1 was 62±14 years compared with 52±9 years in clinic 2 (P &lt; 0.01). There was 100% documentation of weight, BP and HR on every visit. The mean weight in clinic 1 was insignificantly lower compared with clinic 2 (202±61 vs 218±60 lbs respectively; P = 0.06). SBP was similar in both clinics (132±18 vs 130±21 mmHg respectively; P = 0.38). HR was lower in clinic 1 compared with clinic 2 (67±10 vs 77±15 BPM respectively; P &lt; 0.01). Lipid profiles, which required a separate visit to the lab and extra charge, were documented in 93% of patients in clinic 1 versus only 34% of patients in clinic 2. LDL cholesterol was lower in clinic 1 compared with clinic 2 (88±34 vs 106±35 mg/dL respectively; P=0.01). While HDL was similar in both clinics (48 ± 14 in clinic 1 versus 46 ± 15 mg/dL in clinic 2; P = NS), non-HDL was lower, at 115 ± 38 in clinic 1 versus 136 ± 40 mg/dL in clinic 2 (P &lt; 0.01). Discussion: Hypertension and dyslipidemia are major health problem. Adequate control of blood pressure and LDL cholesterol correlate with better cardiovascular outcomes. Our data demonstrate that both faculty and fellow clinics achieved mean BP of &lt; 140/90 mmHg, with 100% documentation. However, documentation and control of lipids appear to be more challenging in indigent patients due to the extra burden and cost of undergoing lab tests. Compliance with medications and the prescription of affordable generic, often less potent, lipid-lowering therapy to indigent patients in the fellow clinic may also play a role in the higher LDL levels compared with the faculty clinic. Efforts at improving the adherence of all patients to preventive therapy aimed at achieving guideline-based BP and lipid targets should be included in quality improvement projects during residency training.
Unintended Pregnancy
Authors: Mike Mitka
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Thermodynamic Atlas of Proteomes Reveals Energetic Innovation across the Tree of Life
Authors: Alexander F Chin, James O Wrabl, Vincent J Hilser
Journal: Molecular Biology and Evolution (2022)

Protein stability is a fundamental molecular property enabling organisms to adapt to their biological niches. How this is facilitated and whether there are kingdom specific or more general universal strategies are unknown. A principal obstacle to addressing this issue is that the vast majority of proteins lack annotation, specifically thermodynamic annotation, beyond the amino acid and chromosome information derived from genome sequencing. To address this gap and facilitate future investigation into large-scale patterns of protein stability and dynamics within and between organisms, we applied a unique ensemble-based thermodynamic characterization of protein folds to a substantial portion of extant sequenced genomes. Using this approach, we compiled a database resource focused on the position-specific variation in protein stability. Interrogation of the database reveals: 1) domains of life exhibit distinguishing thermodynamic features, with eukaryotes particularly different from both archaea and bacteria; 2) the optimal growth temperature of an organism is proportional to the average apolar enthalpy of its proteome; 3) intrinsic disorder content is also proportional to the apolar enthalpy (but unexpectedly not the predicted stability at 25 °C); and 4) secondary structure and global stability information of individual proteins is extractable. We hypothesize that wider access to residue-specific thermodynamic information of proteomes will result in deeper understanding of mechanisms driving functional adaptation and protein evolution. Our database is free for download at https://afc-science.github.io/thermo-env-atlas/ (last accessed January 18, 2022).
Request for Specimens From Organ Transplant Patients Who Developed Lymphomas
Journal: JNCI Journal of the National Cancer Institute (1979)

Request for Specimens From Organ Transplant Patients Who Developed Lymphomas JNCI: Journal of the National Cancer Institute, Volume 62, Issue 5, May 1979, Page 1319, https://doi.org/10.1093/jnci/62.5.1319 Published: 01 May 1979
Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations.
Authors: Yin-Hsun Feng, Wu-Chou Su, Do-Youn Oh, Lin Shen, Kyu-Pyo Kim, Xiufeng Liu, Huimin Liao, Min Qing, Jiaqi Qian, Spyros Triantos, Hussein Sweiti, Joon Oh Park
Journal: Journal of Clinical Oncology (2022)

430 Background: Pts with CCA progressing after first-line therapy have limited treatment options. We report an updated analysis of the ongoing LUC2001 open-label, multicenter, phase 2a study (NCT02699606) investigating the efficacy and safety of erdafitinib in Asian pts with advanced CCA and FGFR alterations who progressed after ≥1 prior systemic treatment. Methods: Eligible adults (aged ≥18 years) received erdafitinib 8 mg once daily (QD) with pharmacodynamically guided up-titration to 9 mg QD. The primary endpoint was objective response rate (ORR; RECIST 1.1); secondary endpoints included best overall response (BOR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Survival estimates were determined by the Kaplan–Meier method. Results: Of 232 patients with CCA who underwent molecular screening, 39 (16.8%) had FGFR alterations (21 [9.1%] fusions and 19 [8.2%] mutations). Overall, 22 (9.5%) eligible pts (median age, 52 [range, 29–69] years) were enrolled and received treatment. Median follow-up was 22.4 (range, 2.3–47.0) months; median treatment duration was 6.2 (range, 1.5–35.6) months. All 22 pts received ≥1 line of prior systemic therapy and 12 (55.0%) pts had ≥2 prior lines of therapy. The ORR was 40.9% (95% CI, 20.7%–63.6%) and median time to response was 1.8 (range, 1.5–5.6) months. Median DOR was 7.3 (95% CI, 3.7–17.5) months, median PFS was 5.6 (95% CI, 3.6–12.7) months, and median OS was 40.2 (95% CI: 9.9–not estimable) months (Table). Responses were observed in 8/14 pts with FGFR fusions and 1/8 pts with FGFR mutations and in pts who received 1 or ≥2 prior lines of therapy. All 22 pts had ≥1 treatment-emergent adverse event (TEAE), the most common being dry mouth (15/22 [68.2%]) and stomatitis (14/22 [63.6%]). Grade ≥3 TEAEs occurred in 15/22 (68.2%) pts (11/22 [50.0%] were treatment related), of which the most common were stomatitis (3/22 [13.6%]) and alanine aminotransferase (ALT) increased (3/22 [13.6%]); 11/22 (50.0%) pts had ≥1 serious TEAE (1/22 [4.5%] pts had a serious treatment-related TEAE). A TEAE leading to death occurred in 1 patient (sepsis; not treatment-related). Conclusions: Asian pts with advanced CCA and FGFR alterations treated with erdafitinib had durable efficacy and a manageable safety profile, supporting the earlier findings of erdafitinib benefit in this population. Clinical trial information: NCT02699606. [Table: see text]
An Acknowledgment
Authors: R. G. Pearcey
Journal: Journal of Clinical Oncology (2002)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.11.2761 Journal of Clinical Oncology - published online before print September 21, 2016 An Acknowledgment R. G. PearceyxR. G. PearceySearch for articles by this author Show More Cross Cancer Institute, Edmonton, Alberta, Canada https://doi.org/10.1200/JCO.2002.20.11.2761 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Limitation a novel lysophosphatic acid analog attenuates ischemia-reperfusion injury Christian Zellner, Richard E. Sievers, Amanda E. M. Browne, Samuil R. Umansky, J. Graham Goddard, William W. Parmley, Kanu Chatterjee, Randall J. Lee. University of California, San Francisco, San Francisco, CA, LXR Biotechnology Inc., Richmond, CA
Journal: Journal of the American College of Cardiology (2001)
Birth defects and vaginal spermicides
Authors: S. Shapiro
Journal: JAMA (1982)

In a cohort study of 50,282 pregnancies recruited between 1958 and 1965, there were 462 gravidae who used nonmercurial spermicides (mostly nonoxynol-9 and octoxynol); the estimated rate ratio for major malformations was 0.9 (95% confidence limits, 0.6 to 1.6). There were also 889 women who used phenylmercuric acetate (no longer available as a spermicide); the corresponding rate ratio was 0.9 (0.6 to 1.3). Limb reduction deformities, neoplasms, Down's syndrome, and hypospadias did not occur in excess in children exposed to spermicides. (<i>JAMA</i>1982;247:2381-2384)
Income Tax Credit for Charity Practice of Physicians
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Update to living systematic review on covid-19 in pregnancy
Journal: BMJ (2021)

Update to living systematic review on covid-19 in pregnancyThis living systematic review on coronavirus disease 2019 (covid-19) by Allotey and colleagues (BMJ 2020;370:m3320) has been updated.For the latest update, visit doi:.This update includes 192 studies (64 676 pregnant and recently pregnant women), 115 of which were new additions to the review.The prevalence of covid-19 in pregnant and recently pregnant women remained unchanged between this update and the original version of the living systematic review.Pregnant women continue to be at increased risk of severe covid-19.In addition to high body mass index and advancing maternal age, evidence suggests that non-white ethnic origin might also be a risk factor for severe covid-19.More data are needed to robustly assess the association between pregnancy specific risk factors and covid-19 related outcomes.
Clinical characteristics, treatment, and oncological outcomes in patients with ampullary cancer at a reference center in Mexico.
Authors: Lucero Itzel Torres Valdiviezo, Karla Lucero Rodríguez Flores, Vanessa Rosas Rosas Camargo, Alejandro Noguez-Ramos, Mónica Isabel Meneses Medina, Ximena Rosas Flota, Armando Gamboa Dominguez, Fidel David Huitzil Melendez
Journal: Journal of Clinical Oncology (2022)

617 Background: Ampullary cancer (AC) represents 0.2% of gastrointestinal cancers. Given the rarity of the disease, information regarding treatment strategies and outcomes derives from studies that include the different types of periampullary cancers, which constitute a heterogeneous group. Our aim was to describe the clinical characteristics, treatment modalities and outcomes in patients (pts) with true AC treated at our institution. Methods: A retrospective review of medical records of all consecutive pts with histological diagnosis of AC evaluated at our institution from Jan 2009-Dec 2019. Clinical, pathological and laboratory variables at diagnosis were recorded. Overall survival (OS) was estimated by Kaplan-Meier and compared with the Log-rank test. Statistical significance was determined at P&lt;0.05. Results: 133 pts with AC were included. Median age was 62 yo (IQR 53-70), 51.9% were women. 25% had ampullary adenoma history. Symptoms at diagnosis: 89% jaundice, 63% weight loss and 56% abdominal pain. Median laboratory values were total bilirubin 1.7 mg/dL (0.7-5.1), albumin 3.7 g/dL (3.1-4.2), hemoglobin 12.6 g/dL (10.9-14.2), carbohydrate antigen (CA) 19-9 34.7 U/mL (6.4-113.9) and carcinoembryonic antigen (CEA) 2.6 ng/mL (1.2-4.2). Most tumors were moderately differentiated (59%). Histologic subtypes of adenocarcinoma were available in 84 pts: intestinal 46.4%, pancreaticobiliary 39.3% and mixed 14.3%. Stage at diagnosis was localized (46%), locally advanced N+ (29%) and advanced (25%). For those with localized/locally advanced disease, 91% (91/100) underwent surgical resection, 25.3% (23/91) received adjuvant chemotherapy (ChT), 69.6% (16/23) received single agent and 30.4% (7/23) duplet. Pts who received adjuvant Cht presented N+ in 69.6%, moderate differentiation in 73.9%, intestinal 47.8% and pancreaticobiliary subtype 43.5%. In advanced setting, 63.6% (21/33) received palliative Cht, 66.7% received a duplet regimen. Median OS was 32.8 (22.9-42.8) months (mos). Median OS according to stage was 152.1, 28.1 and 10.2 mos for localized, locally advanced, and advanced, respectively (P&lt;0.001). OS univariate analysis is shown in table. Conclusions: Most of pts presented with localized/locally advanced disease, were eligible to surgical resection and had a better survival. For those with N+ disease it is required to evaluate the role of adjuvant Cht. In the advanced setting, Cht improves prognosis.[Table: see text]
Stereotactic body radiotherapy (SBRT) with functional treatment planning in patients with hepatocellular carcinoma (HCC) and advanced hepatic cirrhosis: Survival outcomes and toxicity.
Authors: Alexander V. Kirichenko, Shaakir Hasan, Yun Liang, Danny Lee, Aishvarya Godla, Paul Renz, Stephen Abel, Tadahiro Uemura, Lorenzo Machado, Ngoc Thai
Journal: Journal of Clinical Oncology (2022)

460 Background: To evaluate outcomes and dosimetric parameters of ablative stereotactic body radiotherapy (SBRT) with functional treatment planning for localized hepatocellular carcinoma (HCC) in patients with Child-Pugh B (CP-B) hepatic cirrhosis. Methods: Liver SPECT with 99m Tc-sulfur colloid was co-registered to 3D-CT for identification and avoidance of functional hepatic parenchyma during SBRT in patients with advanced cirrhosis. Functional liver volumes (FLV-SPECT) were compared to anatomical liver volumes, as were dosimetric parameters when radiation dose constraints were adapted exclusively to FLV-SPECT. Hepatic function, toxicity, and radiographic response were documented every 4–6 months following SBRT. Results: With a median follow-up of 25 months 37 patients (48 lesions treated) with CP-B cirrhosis received SBRT to a median dose 48 Gy (4–5 fractions). FLV-SPECT volume loss (509 cc or 41.3%, p &lt; 0.001) was observed in all patients, while the functional and anatomical liver volumes matched well in a control group of non-cirrhotic/non-HCC patients. While tumors received ablative irradiation, mean dose to FLV-SPECT was maintained at 1.3 – 16 Gy (median 9.17 Gy), well below the liver threshold tolerance to radiation. Seventeen patients successfully completed liver transplant at a median time to transplant of 6.5 months. The dropout rate from the transplant list was 9 % with intrahepatic progression outside treated tumors. Eight of 10 patients with intrahepatic progression received additional SBRT during follow-up. Overall 2-year survival rate was 65% with no incidence of RILD or CP class migration from B to C was observed at 6+ months post SBRT. Two patients completed liver SBRT on a hybrid linear accelerator combined with MRI scanner (Unity MR-Linac, Elekta) utilizing Super-Paramagnetic Iron Oxide (SPIO) nanoparticle agent as an alternative contrast media for functionally active liver parenchyma. Prolonged SPIO-contrast retention also allowed per fraction treatment plan adaptation and enhanced tumor imaging. Conclusions: SBRT planning with 99m Tc sulfur colloid SPECT allows identification and conformal avoidance of residual functionally active hepatic parenchyma in patients with CP-B cirrhosis. We report high local control and low toxicity leading to satisfactory pre- and post-liver transplant outcomes. Prospective clinical trial investigating MRI-SPIO functional treatment planning for liver SBRT is ongoing at our institution.
Correction
Journal: BMJ (1945)

principle of an independent alternative service, usable without incurring financial disability.It certainly seems amazing that above all else the Council of the B.M.A. should apparently have ignored the article at a time when one would have imagined that every possible means would have been explored in order to find a certain method of preserving real freedom for our patients-and, incidentally, for ourselves.-Iam, etc., Hungerford, Berks.
Persistent hesitancy for SARS-CoV-2 vaccines among healthcare workers in the United Kingdom: analysis of longitudinal data from the UK-REACH cohort study
Authors: Christopher A. Martin, Katherine Woolf, Luke Bryant, Sue Carr, Laura J. Gray, Amit Gupta, Anna L. Guyatt, Catherine John, Carl Melbourne, I. Chris McManus, Joshua Nazareth, Laura B. Nellums, Martin D. Tobin, Daniel Pan, Kamlesh Khunti, Manish Pareek
Journal: The Lancet Regional Health - Europe (2022)
Ultrasound enhances therapeutic gene expression in ischemic pig myocardium Peter Schratzberger, Tengiz Tkebuchava, Rudolf Kirchmair, Charles E. Milliken, Ferdinand Bahlmann, Oren Tepper, Atsuhiko Kawamoto, Hideki Iwaguro, Roberto Pola, Robert F. Zuk, Axel F. Brisken, Peter R. Vale, Jeffrey M. Isner. Cardiovascular Research and Vascular medicine, St. Elisabeth Medical Center, Tufts University, Boston, MA PharmaSonics, Inc., Sunnyvale, CA
Journal: Journal of the American College of Cardiology (2001)
Hospital outcomes of community-acquired COVID-19 versus influenza: Insights from the Swiss hospital-based surveillance of influenza and COVID-19
Authors: Georg Marcus Fröhlich, Marlieke E. A. De Kraker, Mohamed Abbas, Olivia Keiser, Amaury Thiabaud, Maroussia Roelens, Alexia Cusini, Domenica Flury, Peter W. Schreiber, Michael Buettcher, Natascia Corti, Danielle Vuichard-Gysin, Nicolas Troillet, Julien Sauser, Roman Gaudenz, Lauro Damonti, Carlo Balmelli, Anne Iten, Andreas Widmer, Stephan Harbarth, Rami Sommerstein
Journal: Eurosurveillance (2022)

Background Since the onset of the COVID-19 pandemic, the disease has frequently been compared with seasonal influenza, but this comparison is based on little empirical data. Aim This study compares in-hospital outcomes for patients with community-acquired COVID-19 and patients with community-acquired influenza in Switzerland. Methods This retrospective multi-centre cohort study includes patients &gt; 18 years admitted for COVID-19 or influenza A/B infection determined by RT-PCR. Primary and secondary outcomes were in-hospital mortality and intensive care unit (ICU) admission for patients with COVID-19 or influenza. We used Cox regression (cause-specific and Fine-Gray subdistribution hazard models) to account for time-dependency and competing events with inverse probability weighting to adjust for confounders. Results In 2020, 2,843 patients with COVID-19 from 14 centres were included. Between 2018 and 2020, 1,381 patients with influenza from seven centres were included; 1,722 (61%) of the patients with COVID-19 and 666 (48%) of the patients with influenza were male (p &lt; 0.001). The patients with COVID-19 were younger (median 67 years; interquartile range (IQR): 54–78) than the patients with influenza (median 74 years; IQR: 61–84) (p &lt; 0.001). A larger percentage of patients with COVID-19 (12.8%) than patients with influenza (4.4%) died in hospital (p &lt; 0.001). The final adjusted subdistribution hazard ratio for mortality was 3.01 (95% CI: 2.22–4.09; p &lt; 0.001) for COVID-19 compared with influenza and 2.44 (95% CI: 2.00–3.00, p &lt; 0.001) for ICU admission. Conclusion Community-acquired COVID-19 was associated with worse outcomes compared with community-acquired influenza, as the hazards of ICU admission and in-hospital death were about two-fold to three-fold higher.
Unreviewed Reports
Authors: D Wheeler
Journal: BMJ (1984)

Unreviewed ReportsAtypical polyneuropathy complicating rectal carcinoma A 60 year old man presented with a mixed asymmetrical peri- pheral neuropathy and bilateral lower motor neuron facial palsy.Cerebrospinal fluid analysis and electroneurographic studies sug- gested a carcinomatous neuropathy.A large rectal carcinoma (Duke's stage C) was partially excised at laparotomy.The neuro- pathy progressed gradually, and he died 14 weeks postoperatively.At necropsy tumour was confined to the pelvis.Although a mixed peripheral neuropathy is the most common non-metastatic com- plication of cancer, we have found only two other reports of an association with rectal tumour and only one of the facial nerve being affected by any tumour.-